Plain-English translation of NCT07513883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Heart failure patients who have experienced significant recovery—where their heart function has returned to near-normal—typically continue taking four different medications for life. This trial is testing whether it's safe to reduce that to just two medications in carefully selected patients. Researchers will follow participants for two years to see if their heart function stays stable with fewer drugs.
Current guidelines recommend lifelong treatment with all four medications even after recovery, but there's limited evidence that all four are necessary. Taking fewer medications could reduce costs, side effects, and the burden of managing multiple daily pills—while still keeping patients safe.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either continue all four medications as usual, or gradually reduce to just two medications under close supervision. Over two years, you'll have regular visits involving heart imaging tests (echocardiograms), blood tests, and check-ins with your care team to ensure your heart function remains stable. Researchers will track whether you experience any serious events like hospitalization or worsening symptoms.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Belgium